Skip to main content

View Resource

Published

Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial.
Oppegaard O. The Lancet Infectious Diseases 2026;:https://doi.org/10.1016/S1473-3099(26)00244-6.
[Long-term symptoms are common after acute COVID-19, particularly fatigue, cognitive problems, and dyspnoea. Treatment with nirmatrelvir–ritonavir for acute COVID-19 was associated with a significant reduction in the risk of long COVID at 3 months’ follow-up. The limited sample size precludes firm conclusions, and further clinical trials are warranted.]
Available with an NHS OpenAthens password
Age Groups
Adults
Conditions and Lifestyle Factors
Coronavirus Infections
Settings
Community Clinics
General Practice
Staff Groups
Drug Therapy
Medic